Coronary CT angiog- raphy versus standard evaluation in acute chest pain. N Engl J Med. 2012;367:299 308. 206. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012;366:1393 403. 207. Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomog- raphy angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009;53:1642 50. 208. Udelson JE, Beshansky JR, Ballin DS, et al. Myocardial perfusion imag- ing for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA. 2002;288:2693 700. 209. Kontos MC, Jesse RL, Schmidt KL, et al. Value of acute rest sestamibi perfusion imaging for evaluation of patients admitted to the emergency department with chest pain. J Am Coll Cardiol. 1997;30:976 82. 210. Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet. 2011;377:1077 84. 211. Gibbons RJ. Chest pain triage in the ED: is CT coronary angiography the answer? J Nucl Cardiol. 2012;19:404 6. 212. Anderson JL,Adams CD,Antman EM, et al.ACC/AHA 2007 guidelines for themanagementofpatientswithunstableangina/nonST-elevationmyocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148 304. 213. Farquhar H, Weatherall M, Wijesinghe M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009;158:371 7. 214. Cabello JB, Burls A, Emparanza JI, et al. Oxygen therapy for acute myo- cardial infarction. Cochrane Database Syst Rev. 2010:CD007160. 215.


Oxygen therapy for acute myo- cardial infarction. Cochrane Database Syst Rev. 2010:CD007160. 215. Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in car- diac patients. J Am Coll Cardiol. 2010;56:1013 6. 216. Goldstein RE, Rosing DR, Redwood DR, et al. Clinical and circulatory effects of isosorbide dinitrate. Comparison with nitroglycerin. Circulation. 1971;43:629 40. 217. Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol. 1990;16:936 40. 218. Kohli RS, Rodrigues EA, Kardash MM, et al. Acute and sustained effects of isosorbide 5-mononitrate in stable angina pectoris. Am J Cardiol. 1986;58:727 31. 219. Kaplan K, Davison R, Parker M, et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol. 1983;51:694 8. 220. Melandri G, Branzi A, Tartagni F, et al. Haemodynamic effects of meto- prolol and intravenous nitroglycerin versus metoprolol alone in patients with acute myocardial infarction. Eur Heart J. 1987;8:592 6. 221. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988;1:1088 92. 222. Charvat J, Kuruvilla T, al AH. Beneficial effect of intravenous nitro- glycerin in patients with non-Q myocardial infarction. Cardiologia. 1990;35:49 54. 223. Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo- controlled study. J Intern Med. 1998;243:25 31. 224. Peacock WF, Emerman CL, Young J. Nesiritide in congestive heart fail- ure associated with acute coronary syndromes: a pilot study of safety and efficacy. J Card Fail. 2004;10:120 5. 225. Cheitlin MD, Hutter AM Jr., Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation. 1999;99:168 77. 226.


Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation. 1999;99:168 77. 226. Webb DJ, Freestone S,Allen MJ, et al. Sildenafil citrate and blood-pressure- lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83:21C 8C. 227. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855 60. 228. Knight CJ, Panesar M, Wilson DJ, et al. Different effects of cal- cium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation. 1997;95:125 32. 229. Mahmarian JJ, Moye LA, Chinoy DA, et al.Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective random- ized, double-blind, placebo-controlled trial. Circulation. 1998;97:2017 24. 230. Garcia-Dorado D, Permanyer-Miralda G, Brotons C, et al. Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates. Clin Cardiol. 1999;22:303 8. 231. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and car- diovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1058 72. and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149:1043 9. 233. Iakobishvili Z, Cohen E, Garty M, et al. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care. 2011;13:76 80. 234. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarc- tion associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906 13. 235. Kearney PM, Baigent C, Godwin J, et al.


2006;113:2906 13. 235. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302 8. 236. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25:205 9. 237. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiin- flammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634 42. 238. Gibson CM, Pride YB, Aylward PE, et al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis. 2009;27:11 7. 239. Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and gov- ernance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157:606 12. 240. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422 37. 241. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocar- dial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 7. 242. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker ther- apy: results from the American College of Cardiology s NCDR((R)). Am Heart J. 2011;161:864 70. 243. de Peuter OR, Lussana F, Peters RJ, et al. A systematic review of selec- tive and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure.


A systematic review of selec- tive and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284 94. 244. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral meto- prolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622 32. 245. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med. 1983;308:614 8. 246. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385 90. 247. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post- Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525 30. 248. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double- blind, randomized, multicenter trial. N Engl J Med. 1986;315:423 9. 249. Effect of verapamil on mortality and major events after acute myocar- dial infarction (the Danish Verapamil Infarction Trial II DAVIT II). Am J Cardiol. 1990;66:779 85. 250. Moss AJ, Oakes D, Rubison M, et al. Effects of diltiazem on long- term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol. 1991; 68:429 33. 251. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mor- tality in patients with coronary heart disease. Circulation. 1995;92:1326 31. 252.


Dose-related increase in mor- tality in patients with coronary heart disease. Circulation. 1995;92:1326 31. 252. Early treatment of unstable angina in the coronary care unit: a ran- domised, double blind, placebo controlled comparison of recurrent isch- aemia in patients treated with nifedipine or metoprolol or both. Report of the Holland Interuniversity Nifedipine/ Metoprolol Trial (HINT) Research Group. Br Heart J. 1986;56:400 13. 253. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronaryspasticangina)(JCS2008):digestversion.CircJ.2010;74:1745 62. 254. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with car- diovascular disease: an overview of randomized trials. Clin Cardiol. 1998;21:633 41. 255. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antago- nist reinfarction Italian study (CRIS). Am J Cardiol. 1996;77:365 9. 256. Smith NL, Reiber GE, Psaty BM, et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol. 1998;32:1305 11. 257. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. Am J Cardiol. 1997;79:738 41. 258. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A 25A. 259. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consen- sus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123:2434 506. 260. Chaitman BR, Pepine CJ, Parker JO, et al.


2011;123:2434 506. 260. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina fre- quency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309 16. 261. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375 82. 262. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113:2462 72. 263. Morrow DA, Scirica BM, Karwatowska- Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST- elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775 83. 264. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double- blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53:1510 6. 265. Stone GW, Ohman EM, Miller MF, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003;41:1940 5. 266. Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon coun- terpulsation during high-risk percutaneous coronary intervention: a ran- domized controlled trial. JAMA. 2010;304:867 74. and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011;306:1329 37. 268. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon sup- port for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287 96. 269. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovas- cular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438 45. 270.


Meta-analysis of cardiovas- cular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438 45. 270. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. 271. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moder- ate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. 272. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001 9. 273. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002;89:860 1. 274. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711 8. 275. Garg R,Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450 6. 276. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145 53. 277. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricu- lar dysfunction, or both. N Engl J Med. 2003;349:1893 906. 278. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547 59. 279.


Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547 59. 279. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309 21. 280. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intol- erant to angiotensin-converting enzyme inhibitors: a randomised con- trolled trial. Lancet. 2008;372:1174 83. 281. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581 8. 282. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long- term randomized controlled trials. Arch Intern Med. 2006;166:787 96. 283. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97:2202 12. 284. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e401 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669 85. 285. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortal- ity and morbidity in patients with left ventricular dysfunction after myo- cardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. 286. Kaul P, Ezekowitz JA,Armstrong PW, et al. Incidence of heart failure and mortality after acute coronary syndromes.Am Heart J. 2013;165:379 85. 287.


Incidence of heart failure and mortality after acute coronary syndromes.Am Heart J. 2013;165:379 85. 287. Rossignol P, Menard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58:1958 66. 288. Baigent C, Blackwell L, Collins R, et al.Aspirin in the primary and second- ary prevention of vascular disease: collaborative meta-analysis of individ- ual participant data from randomised trials. Lancet. 2009;373:1849 60. 289. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494 502. 290. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544 54. 291. CAPRIE Steering Committee. A randomised, blinded, trial of clopido- grel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329 39. 292. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930 42. 293. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045 57. 294. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive man- agement: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527. 295. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatideinacutecoronarysyndromes.NEnglJMed.2009;360:2176 90. 296. Mehta SR, Yusuf S, Peters RJ, et al.


Early versus delayed, provisional eptifibatideinacutecoronarysyndromes.NEnglJMed.2009;360:2176 90. 296. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopi- dogrel and aspirin followed by long-term therapy in patients undergo- ing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527 33. 297. Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV Acute Coronary Syndrome) Trial. Circulation. 2003;107:437 42. 298. Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012;164:153 62. 299. Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresis- tance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377 85. 300. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percu- taneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923 32. 301. Plaivx. Bristol-Myers Squibb: New York, NY. 2013. 302. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi- dogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001 15. 303. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297 309. 304. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasu- grel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999 1010. 305. Becker RC, Bassand JP, Budaj A, et al.


2013;369:999 1010. 305. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32:2933 44. 306. AstraZeneca. Brilinta REMS document. NDA 22-433. 2011. 307. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010;31:35 49. 308. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coro- nary syndromes: the ACUITY Timing trial. JAMA. 2007;297:591 602. 309. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfrac- tionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45 54. 310. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203 16. 311. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary interven- tion: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907 19. 312. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syn- dromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50:1742 51. 313. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparininacutecoronarysyndromes.NEnglJMed.2006;354:1464 76. 314. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfrac- tionated heparin for percutaneous coronary intervention in acute coro- nary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339 49. 315.


Low-dose vs standard-dose unfrac- tionated heparin for percutaneous coronary intervention in acute coro- nary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339 49. 315. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment eleva- tion myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519 30. 316. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811 5. 317. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105 11. 318. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery dis- ease. The RISC Group. Lancet. 1990;336:827 30. 319. Cohen M, Adams PC, Hawkins L, et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol. 1990;66:1287 92. 320. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy inAcute Coronary Syndromes Research Group. Circulation. 1994;89:81 8. 321. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39 45. 322. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313 8. 323.


Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313 8. 323. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S 43S. 324. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol. 2000;36:693 8. 325. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfraction- ated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89 96. 326. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042 50. 327. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J. 1999;138:313 8. 328. Linkins LA, DansAL, Moores LK, et al. Treatment and prevention of hep- arin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e495S 530S. 329. Indications for fibrinolytic therapy in suspected acute myocardial infarc- tion: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Lancet. 1994;343:311 22. 330. Shishehbor MH, Topol EJ, Mukherjee D, et al.


1994;343:311 22. 330. Shishehbor MH, Topol EJ, Mukherjee D, et al. Outcome of multivessel coronary intervention in the contemporary percutaneous revasculariza- tion era. Am J Cardiol. 2006;97:1585 90. 331. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411 20. 332. Boden WE, O Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338:1785 92. 333. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095 104. 334. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST- elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360:743 51. 335. McCullough PA, O Neill WW, Graham M, et al. A prospective random- ized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in throm- bolytic exclusion (MATE) trial. J Am Coll Cardiol. 1998;32:596 605. 336. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of pro- longed antithrombotic pretreatment ( cooling-off strategy) before inter- vention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003;290:1593 9. 337. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/ angioplasty in evolving Non-ST segment elevation myocardial infarc- tion: an open multicenter randomized trial. The VINO Study. Eur Heart J. 2002;23:230 8. 338. Damman P, Hirsch A, Windhausen F, et al.


2002;23:230 8. 338. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coro- nary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55:858 64. 339. Invasive compared with non-invasive treatment in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354:708 15. 340. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment eleva- tion acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55:2435 45. 341. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strat- egies in patients with acute coronary syndromes: a collaborative meta- analysis of randomized trials. JAMA. 2005;293:2908 17. 342. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interven- tional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366:914 20. 343. Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis.Ann Intern Med. 2013;158:261 70. 344. Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol. 2001;38:41 8. 345. Dolor RJ, Melloni C, Chatterjee R, et al. Treatment strategies for women with coronary artery disease. Comparative effectiveness review no. 66. Rockville, MD: Agency for healthcare Research and Quality. 2012. AHRQ publication no. 12-EHC070-EF. Available at: http://www.effectivehealthcare.ahrq.gov/ reports/final.cfm.Accessed July 30, 2014. 346.


AHRQ publication no. 12-EHC070-EF. Available at: http://www.effectivehealthcare.ahrq.gov/ reports/final.cfm.Accessed July 30, 2014. 346. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288: 3124 9. 347. O Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012;60:106 11. 348. Raman SV, Simonetti OP, Winner MW III, et al. Cardiac magnetic reso- nance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55:2480 8. 349. Starling MR, Crawford MH, Kennedy GT, et al. Treadmill exercise tests predischarge and six weeks post-myocardial infarction to detect abnor- malities of known prognostic value. Ann Intern Med. 1981;94:721 7. 350. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiogra- phy is an accurate and cost-efficient technique for detection of coronary artery disease in women. J Am Coll Cardiol. 1995;26:335 41. 351. Larsson H, Areskog M, Areskog NH, et al. Should the exercise test (ET) be performed at discharge or one month later after an episode of unsta- ble angina or non-Q-wave myocardial infarction? Int J Card Imaging. 1991;7:7 14. 352. Nyman I, Larsson H,Areskog M, et al. The predictive value of silent isch- emia at an exercise test before discharge after an episode of unstable cor- onary artery disease. RISC Study Group. Am Heart J. 1992;123:324 31. 353. Mahmarian JJ, Shaw LJ, Filipchuk NG, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myo- cardial perfusion imaging in identifying a low-risk group for early hos- pital discharge after acute myocardial infarction. J Am Coll Cardiol. 2006;48:2448 57. 354.


A multinational study to establish the value of early adenosine technetium-99m sestamibi myo- cardial perfusion imaging in identifying a low-risk group for early hos- pital discharge after acute myocardial infarction. J Am Coll Cardiol. 2006;48:2448 57. 354. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998;98:1622 30. 355. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary inter- vention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645 53. 356. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32:2125 34. 357. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effec- tiveness of revascularization strategies. N Engl J Med. 2012;366:1467 76. 358. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass sur- gery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607 16. 359. Bangalore S, Faxon DP. Coronary intervention in patients with acute coronary syndrome: does every culprit lesion require revascularization? Curr Cardiol Rep. 2010;12:330 7. 360. Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multives- sel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J. 2008;155:140 6. 361. Brener SJ, Murphy SA, Gibson CM, et al. Efficacy and safety of multi- vessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002;90:631 3. 362. Palmer ND, Causer JP, Ramsdale DR, et al.


2002;90:631 3. 362. Palmer ND, Causer JP, Ramsdale DR, et al. Effect of completeness of revascularization on clinical outcome in patients with multivessel disease presenting with unstable angina who undergo percutaneous coronary intervention. J Invasive Cardiol. 2004;16:185 8. 363. Shishehbor MH, Lauer MS, Singh IM, et al. In unstable angina or non- ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol. 2007;49:849 54. 364. Zapata GO, Lasave LI, Kozak F, et al. Culprit-only or multivessel per- cutaneous coronary stenting in patients with non-ST-segment elevation acute coronary syndromes: one-year follow-up. J Interv Cardiol. 2009; 22:329 35. 365. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306:53 61. 366. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319 25. 367. Hoenig MR, Doust JA, Aroney CN, et al. Early invasive versus conser- vative strategies for unstable angina and non-ST-elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2006:CD004815. 368. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J. 2009;30:900 7. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e403 369. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:576S 99S. 370. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 1987;76:125 34. 371. Schomig A, Neumann FJ, Kastrati A, et al.


1987;76:125 34. 371. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary- artery stents. N Engl J Med. 1996;334:1084 9. 372. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse car- diac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation. 2001;103:1403 9. 373. Steinhubl DR, Deal DB. Optimal duration of pretreatment with clopido- grel prior to PCI: data from the CREDO trial. Circulation. 2003;108(suppl I):I1742. Abstract. 374. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005:111:1153 9. 375. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pre- treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI- CLARITY study. JAMA. 2005;294:1224 32. 376. von Beckerath N, Taubert D, Pogatsa-Murray G, et al.Absorption, metab- olization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112:2946 50. 377. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97:98 105. 378. Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2010;106:1208 11. 379. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose hepa- rin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med.


Platelet glycoprotein IIb/IIIa receptor blockade and low-dose hepa- rin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. 1997;336:1689 96. 380. Boersma E,Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045 8. 381. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623 9. 382. Use of a monoclonal antibody directed against the platelet glycopro- tein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330:956 61. 383. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofi- ban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004;44:14 9. 384. Novel dosing regimen of eptifibatide in planned coronary stent implanta- tion (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356: 2037 44. 385. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to pre- vent Recurrent Events (CURE) study. Circulation. 2003;108:1682 7. 386. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95:1218 22. 387. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 388.


Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 388. Patrono C, Baigent C, Hirsh J, et al.Antiplatelet drugs:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:199S 233S. 389. Lincoff AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT tri- als. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg. 2000;70:516 26. 390. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation. 2002;106:2284 7. 391. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus stan- dard-dose clopidogrel and high-dose versus low-dose aspirin in individu- als undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233 43. 392. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment- elevation acute coronary syndromes. Circulation. 2001;104:2767 71. 393. O Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibi- tor in patients with acute coronary syndromes undergoing percutane- ous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel- Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54:678 85. 394. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost. 2009;102:428 36. 395. Lincoff AM, Bittl JA, Kleiman NS, et al.


2009;102:428 36. 395. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin ver- sus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092 6. 396. Lincoff AM, Bittl JA, Harrington RA, et al. Biva lirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned gly- coprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853 63. 397. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfraction- ated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688 96. 398. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin dur- ing primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218 30. 399. Cohen M, Levine GN, Pieper KS, et al. Enoxaparin 0.3 mg/kg IV sup- plement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv. 2010;75:928 35. 400. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary interven- tion after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658 63. 401. Collet JP, Montalescot G, Golmard JL, et al. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am Heart J. 2004;147:655 61. 402. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163 70. 403. Levine GN, Ferrando T. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutane- ous coronary intervention. J Thromb Thrombolysis. 2004;17:167 71. 404. Steg PG, Mehta S, Jolly S, et al.


2004;17:167 71. 404. Steg PG, Mehta S, Jolly S, et al. Fondaparinux with UnfracTionated hep- arin dUring Revascularization in Acute coronary syndromes (FUTURA/ OASIS 8): a randomized trial of intravenous unfractionated heparin dur- ing percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J. 2010;160:1029 34. 405. Montalescot G, Gallo R, White HD, et al. Enoxaparin versus unfraction- ated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009;2:1083 91. 406. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intra- venous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943 50. 407. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166 286. 408. Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation. 2005;112:1286 92. 409. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000;70:1986 90. 410. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309 17. 411. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol. 2008;52:1693 701. 412. Held C, Asenblad N, Bassand JP, et al.


2008;52:1693 701. 412. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672 84. 413. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combina- tion with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231 7. 414. Prasugrel [Label]. Indianapolis, IN: Eli Lilly and Co, 2009. 415. Firanescu CE, Martens EJ, Schonberger JP, et al. Postoperative blood loss in patients undergoing coronary artery bypass surgery after preop- erative treatment with clopidogrel. A prospective randomised controlled study. Eur J Cardiothorac Surg. 2009;36:856 62. 416. Herman CR, Buth KJ, Kent BA, et al. Clopidogrel increases blood trans- fusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg. 2010;89:397 402. 417. Mehta RH, Sheng S, O Brien SM, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes. 2009;2:583 90. 418. Bizzarri F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban hydro- chloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2001;122:1181 5. 419. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg. 2000;70:866 71. 420. Levine GN, Lincoff AM, Ferguson JJ III, et al. Utilization of catheter- ization and revascularization procedures in patients with non-ST seg- ment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Interv. 2005;66:149 57. 421. Parikh SV, de Lemos JA, Jessen ME, et al.


421. Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coro- nary artery bypass graft surgery for non-ST-segment elevation myocar- dial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). JACC Cardiovasc Interv. 2010;3:419 27. 422. Fox KA, Anderson FA Jr., Dabbous OH, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart. 2007;93:177 82. 423. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and out- comes in patients with non-ST-segment elevation acute coronary syn- dromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006;48:281 6. 424. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revasculariza- tion for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202 8. 425. Kim JH, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J. 2008;156:886 92. 426. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-oper- ative clopidogrel administration in patients with acute coronary syn- dromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2009;53:1965 72. 427. Mukherjee D, Fang J, Chetcuti S, et al. Impact of combination evidence- based medical therapy on mortality in patients with acute coronary syn- dromes. Circulation. 2004;109:745 9. 428. Gluckman TJ, Sachdev M, Schulman SP, et al. A simplified approach to the management of non-ST-segment elevation acute coronary syn- dromes. JAMA. 2005;293:349 57. 429. Dracup K, Alonzo AA, Atkins JM, et al.


2005;293:349 57. 429. Dracup K, Alonzo AA, Atkins JM, et al. The physician s role in mini- mizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program.Working Group on Educational StrategiesTo Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med. 1997;126:645 51. 430. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122:2619 633. 431. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909 17. 432. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplate- let therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634 40. 433. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011;4:522 34. 434. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syn- drome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103:13 28. 435. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433 41. 436. You JJ, Singer DE, Howard PA, et al.


2010;170:1433 41. 436. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e531S 75S. 437. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary a consensus document of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2010;31:1311 8. 438. Deleted in press. 439. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. JAm Coll Cardiol. 2011;57:173 80. 440. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and under- going percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107 15. 441. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assess- ment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577 85. 442. Follow-up to the January 26, 2009, early communication about an ongo- ing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). US Food and Drug Administration. 2014. Available at: http://www.fda.gov/Drugs/ DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ DrugSafetylnformationforHeathcareProfessionals/ucm190784.htm. Accessed June 12, 2014. 443. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and non- fatal myocardial infarction in acute coronary syndrome patients receiv- ing coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237 42. 444.


Cardiovascular death and non- fatal myocardial infarction in acute coronary syndrome patients receiv- ing coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237 42. 444. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopido- grel based on platelet function testing after percutaneous coronary inter- vention: the GRAVITAS randomized trial. JAMA. 2011;305:1097 105. 445. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust anti- platelet therapy for coronary stenting. N Engl J Med. 2012;367:2100 9. 446. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312 9. 447. ShuldinerAR, O Connell JR, Bliden KP, et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849 57. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e405 448. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning . Circulation. 2010;122:537 57. 449. Wenger NK, Froelicher ES, Smith LK, et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. Clin Pract Guidel Quick Ref Guide Clin. 1995:1 23. 450. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128:873 934. 451. Balady GJ, Williams MA, Ades PA, et al.


2013;128:873 934. 451. Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac reha- bilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on CardiovascularNursing,EpidemiologyandPrevention,andNutrition,Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007;115:2675 82. 452. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682 92. 453. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 per- formance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in collabora- tion with the American Academy of Family Physicians and American College of Emergency Physicians. Circulation. 2008;118:2598 648. 454. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010 update: performance measures on cardiac rehabilitation for referral to car- diac rehabilitation/secondary prevention services. Circulation. 2010; 122:1342 50. 455. Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 perfor- mance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services. Circulation. 2007;116:1611 42. 456. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107:3109 16. 457. Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation. 2005;112:2354 63. 458. Pollock ML, Franklin BA, Balady GJ, et al. AHA science advisory.


Pollock ML, Franklin BA, Balady GJ, et al. AHA science advisory. Resistance exercise in individuals with and without cardiovascular dis- ease: benefits, rationale, safety, and prescription: an advisory from the CommitteeonExercise,Rehabilitation,andPrevention,CouncilonClinical Cardiology, American Heart Association. Circulation. 2000;101:828 33. 459. Gondoni LA, Liuzzi A, Titon AM, et al. A simple tool to predict exer- cise capacity of obese patients with ischaemic heart disease. Heart. 2006;92:899 904. 460. Rankin SL, Briffa TG, Morton AR, et al. A specific activity questionnaire to measure the functional capacity of cardiac patients. Am J Cardiol. 1996;77:1220 3. 461. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-adminis- tered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651 4. 462. Morris CK, Myers J, Froelicher VF, et al. Nomogram based on metabolic equivalents and age for assessing aerobic exercise capacity in men. J Am Coll Cardiol. 1993;22:175 82. 463. Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentra- tions. Cholesterol and Recurrent Events CARE. Investigators. J Am Coll Cardiol. 1999;34:106 12. 464. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102 6. 465. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumo- coccal polysaccharide vaccine for adults with immunocompromising con- ditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816 9. 466. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1 24. 467. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxy- genase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633 44. 468. Deleted in press.


McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxy- genase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633 44. 468. Deleted in press. 469. de Feyter PJ, Serruys PW, Arnold A, et al. Coronary angioplasty of the unstable angina related vessel in patients with multivessel disease. Eur Heart J. 1986;7:460 7. 470. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523 34. 471. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849 59. 472. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA. 2002;288:321 33. 473. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post- menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605 13. 474. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized tri- als of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842 57. 475. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481 501. 476. Lonn E,Yusuf S,Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567 77. 477. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578 88. 478. Stampfer MJ, Malinow MR, Willett WC, et al.


2006;354:1578 88. 478. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physi- cians. JAMA. 1992;268:877 81. 479. Imasa MS, Gomez NT, Nevado JB Jr. Folic acid-based intervention in non-ST elevation acute coronary syndromes. Asian Cardiovasc Thorac Ann. 2009;17:13 21. 480. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. 481. Naylor M, Brooten D, Jones R, et al. Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med. 1994;120:999 1006. 482. Coleman EA, Parry C, Chalmers S, et al. The care transitions inter- vention: results of a randomized controlled trial. Arch Intern Med. 2006;166:1822 8. 483. Young W, Rewa G, Goodman SG, et al. Evaluation of a community- based inner-city disease management program for postmyocardial infarc- tion patients: a randomized controlled trial. CMAJ. 2003;169:905 10. 484. Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital dis- charge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150:178 87. 485. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year car- diovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med. 2004;141:446 53. 486. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association sci- entific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with theAmericanAssociation of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005;111:369 76. 487. Suaya JA, Stason WB, Ades PA, et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54:25 33.


Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54:25 33. 488. MMWR Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-2013 Influenza Season. Centers for Disease Control and Prevention. 2012. 489. Krumholz HM, MerrillAR, Schone EM, et al. Patterns of hospital perfor- mance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2:407 13. 490. Bernheim SM, Grady JN, Lin Z, et al. National patterns of risk-standard- ized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3:459 67. 491. Coleman EA. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. J Am Geriatr Soc. 2003;51:549 55. 492. Coleman EA, Boult C. Improving the quality of transitional care for per- sons with complex care needs. J Am Geriatr Soc. 2003;51:556 7. 493. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient s perspective: the care transitions measure. Med Care. 2005;43:246 55. 494. Bernheim SM, Spertus JA, Reid KJ, et al. Socioeconomic disparities in outcomes after acute myocardial infarction.Am Heart J. 2007;153:313 9. 495. RahimiAR, Spertus JA, Reid KJ, et al. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA. 2007;297:1063 72. 496. Smolderen KG, Spertus JA, Reid KJ, et al. The association of cogni- tive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009;2:328 37. 497. Snow V, Beck D, Budnitz T, et al.


2009;2:328 37. 497. Snow V, Beck D, Budnitz T, et al. Transitions of care consensus policy statement American College of Physicians Society of General Internal Medicine-Society of Hospital Medicine American Geriatrics Society- American College of Emergency Physicians Society of Academic Emergency Medicine. J Gen Intern Med. 2009;24:971 6. 498. National Quality Forum. Safe practices for better healthcare: 2010 update. Available at: http://qualityforum.org/projects/safe_practices_2010.aspx. Accessed December 9, 2010. 499. The Joint Commission. 2014 National Patient Safety Goals. Available at: http://www.jointcommission.org/standards_information/npsgs.aspx. Accessed July 30, 2014. 500. National Quality Forum. Preferred practices and performance measures for measuring and reporting care coordination. Available at: http://www. qualityforum.org/Care_Coordination_Measures.aspx. Accessed December 9, 2010. 501. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311:20. 502. Desai MM, Stauffer BD, Feringa HH, et al. Statistical models and patient predictors of readmission for acute myocardial infarction: a systematic review. Circ Cardiovasc Qual Outcomes. 2009;2:500 7. 503. Verouden NJ, Haeck JD, Kuijt WJ, et al. Prediction of 1-year mortal- ity with different measures of ST-segment recovery in all-comers after primary percutaneous coronary intervention for acute myocardial infarc- tion. Circ Cardiovasc Qual Outcomes. 2010;3:522 9. 504. Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from theAmerican College of Physicians. J Am Coll Cardiol. 2007;49:734 9. 505. American College of Chest Physicians. Tobacco dependence treatment toolkit, chestnet.org. 2014. Available at: http://tobaccodependence.chest- net.org/. Accessed July 30, 2014. 506.


2014. Available at: http://tobaccodependence.chest- net.org/. Accessed July 30, 2014. 506. Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878 85. 507. Position statement:American DiabetesAssociation Standards of Medical Care in Diabetes 2013. Diabetes Care. 2013;36(suppl 1):S11 66. 508. Steinke EE, Jaarsma T, Barnason SA, et al. Sexual counseling for indi- viduals with cardiovascular disease and their partners: a consensus doc- ument from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). Circulation. 2013;128:2075 96. 509. Lichtman JH, Bigger JT Jr., Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a sci- ence advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2008;118:1768 75. 510. National Quality Forum (NQF). A comprehensive framework and pre- ferred practices for measuring and reporting cultural competency: a con- sensus report. April 2009. 511. Hospital to Home Quality Initiative. 2013. 512. Wiggins BS, Rodgers JE, DiDomenico RJ, et al. Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by members of the American College of Clinical Pharmacy s Cardiology Practice and Research Network based on the Hospital to Home (H2H) Initiative. Pharmacotherapy. 2013;33:558 80. 513. Effective communication and care coordination. 2013. 514. Institute of Medicine. Cardiovascular disability: updating the Social Security listings. Washington, DC: The National Academies Press, 2010. 515. Alexander KP, Newby LK, Cannon CP, et al.


Washington, DC: The National Academies Press, 2010. 515. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115:2549 69. 516. Gale CP, Cattle BA, Woolston A, et al. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010. Eur Heart J. 2012;33:630 9. 517. Devlin G, Gore JM, Elliott J, et al. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events. Eur Heart J. 2008;29:1275 82. 518. Damman P, Clayton T, Wallentin L, et al. Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - IC. Heart. 2012;98:207 13. 519. Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non- ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004;141:186 95. 520. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17:571 84. 521. Trifiro G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12:611 20. 522. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108 16. 523. Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults: a systematic review. JAMA.


Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults: a systematic review. JAMA. 2012;307:182 92. 524. Fenning S, Woolcock R, Haga K, et al. Identifying acute coronary syn- drome patients approaching end-of-life. PLoS One. 2012;7:e35536. 525. Tinetti ME, Bogardus ST Jr., Agostini JV. Potential pitfalls of disease- specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870 4. 526. Lopes RD,Alexander KP, Manoukian SV, et al.Advanced age, antithrom- botic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;53:1021 30. 527. Lemesle G, Labriolle De, Bonello L, et al. Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians under- going percutaneous coronary intervention. Catheter Cardiovasc Interv. 2009;74:428 35. 528. Summaria F, Romagnoli E, De Luca L, et al. Feasibility and safety of transradial approach and bivalirudin treatment in elderly patients under- going early invasive strategy for ACS: The OLDER Research Project preliminary study. J Cardiovasc Med (Hagerstown). 2012;13:351 2. 529. McKellar SH, Brown ML, Frye RL, et al. Comparison of coronary revas- cularization procedures in octogenarians: a systematic review and meta- analysis. Nat Clin Pract Cardiovasc Med. 2008;5:738 46. 530. Kimura T, Morimoto T, Furukawa Y, et al. Long-term outcomes of coro- nary-artery bypass graft surgery versus percutaneous coronary interven- tion for multivessel coronary artery disease in the bare-metal stent era. Circulation. 2008;118:S199 209. 531. Dacey LJ, Likosky DS, Ryan TJ Jr., et al. Long-term survival after sur- gery versus percutaneous intervention in octogenarians with multivessel coronary disease. Ann Thorac Surg. 2007;84:1904 11. 532. Ramanathan KB, Weiman DS, Sacks J, et al. Percutaneous intervention versus coronary bypass surgery for patients older than 70 years of age with high-risk unstable angina. Ann Thorac Surg. 2005;80: 1340 6.


Percutaneous intervention versus coronary bypass surgery for patients older than 70 years of age with high-risk unstable angina. Ann Thorac Surg. 2005;80: 1340 6. 533. Sheridan BC, Stearns SC, Rossi JS, et al. Three-year outcomes of multivessel revascularization in very elderly acute coronary syndrome patients. Ann Thorac Surg. 2010;89:1889 94. 534. Nissinen J, Wistbacka JO, Loponen P, et al. Coronary artery bypass sur- gery in octogenarians: long-term outcome can be better than expected. Ann Thorac Surg. 2010;89:1119 24. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e407 535. Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortal- ity. JAMA. 2012;307:813 22. 536. Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global RegistryofAcuteCoronaryEvents(GRACE).AmHeartJ.2005;149:67 73. 537. Dodd KS, Saczynski JS, Zhao Y, et al. Exclusion of older adults and women from recent trials of acute coronary syndromes. J Am Geriatr Soc. 2011;59:506 11. 538. Nguyen HL, Goldberg RJ, Gore JM, et al. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis. 2010;21:336 44. 539. Lopes RD, White JA, Tricoci P, et al. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. Int J Cardiol. 2013;167:2580 7. 540. Buber J, Goldenberg I, Kimron L, et al. One-year outcome following cor- onary angiography in elderly patients with non-ST elevation myocardial infarction: real-world data from the Acute Coronary Syndromes Israeli Survey (ACSIS). Coron Artery Dis. 2013;24:102 9. 541. Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56:1683 92. 542. Gurbel PA, Ohman EM, Jeong YH, et al.


2010;56:1683 92. 542. Gurbel PA, Ohman EM, Jeong YH, et al. Toward a therapeutic window for antiplatelet therapy in the elderly. Eur Heart J. 2012;33:1187 9. 543. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:257S 98S. 544. Lopes RD, Subherwal S, Holmes DN, et al. The association of in-hos- pital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarc- tion. Eur Heart J. 2012;33:2044 53. 545. Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the effi- cacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007; 147:304 10. 546. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocar- dial infarction? Circulation. 2007;116:2793 801. 547. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736 47. 548. Alexander KP, Roe MT, Chen AY, et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1479 87. 549. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189 98. 550. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and plannedglycoproteinIIb/IIIablockadeduringpercutaneouscoronaryrevas- cularization: REPLACE-2 randomized trial. JAMA. 2004;292:696 703. 551. Lamberts M, Olesen JB, Ruwald MH, et al.


2004;292:696 703. 551. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrilla- tion patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation .2012;126:1185 93. 552. Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing pat- terns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049 56. 553. Bagnall AJ, Goodman SG, Fox KA, et al. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST- elevation acute coronary syndromes. Am J Cardiol. 2009;103:1530 6. 554. Rittger H, Hochadel M, Behrens S, et al. Age-related differences in diag- nosis, treatment and outcome of acute coronary syndromes: results from the German ALKK registry. EuroIntervention. 2012;7:1197 205. 555. Birkhead JS, Weston CF, Chen R. Determinants and outcomes of coro- nary angiography after non-ST-segment elevation myocardial infarction. A cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Heart. 2009;95:1593 9. 556. Casella G, Scorcu G, Cassin M, et al. Elderly patients with acute coro- nary syndromes admitted to Italian intensive cardiac care units: a Blitz-3 Registry sub-analysis. J Cardiovasc Med (Hagerstown). 2012;13:165 74. 557. Bardakci H, Cheema FH, Topkara VK, et al. Discharge to home rates are significantly lower for octogenarians undergoing coronary artery bypass graft surgery. Ann Thorac Surg. 2007;83:483 9. 558. Krane M, Voss B, Hiebinger A, et al. Twenty years of cardiac surgery in patients aged 80 years and older: risks and benefits. Ann Thorac Surg. 2011;91:506 13. 559. Panesar SS, Athanasiou T, Nair S, et al. Early outcomes in the elderly: a meta-analysis of 4921 patients undergoing coronary artery bypass grafting comparison between off-pump and on-pump techniques. Heart. 2006;92:1808 16. 560. Hochman JS, Sleeper LA, Webb JG, et al.


2006;92:1808 16. 560. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341:625 34. 561. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment ele- vation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292:2096 104. 562. Segev A, Strauss BH, Tan M, et al. Prognostic significance of admis- sion heart failure in patients with non-ST-elevation acute coronary syn- dromes (from the Canadian Acute Coronary Syndrome Registries). Am J Cardiol. 2006;98:470 3. 563. Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational stud- ies. Eur J Heart Fail. 2011;13:773 84. 564. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multi- vessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190 7. 565. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961 72. 566. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coro- nary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352: 2174 83. 567. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percuta- neous coronary intervention provides differential longevity benefit. Ann Thorac Surg. 2006;82:1420 8. 568. Kunadian V, Pugh A, Zaman AG, et al. Percutaneous coronary interven- tion among patients with left ventricular systolic dysfunction: a review and metaanalysis of 19 clinical studies. Coron Artery Dis. 2012;23:469 79. 569. Shah R, Thomson A, Atianzar K, et al.


2012;23:469 79. 569. Shah R, Thomson A, Atianzar K, et al. Percutaneous left ventricular sup- port for high-risk PCI and cardiogenic shock: who gets what? Cardiovasc Revasc Med. 2012;13:101 5. 570. Maini B, Naidu SS, Mulukutla S, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary inter- vention: The USpella Registry. Catheter Cardiovasc Interv. 2012; 80:717 25. 571. Froesch P, Martinelli M, Meier P, et al. Clinical use of temporary per- cutaneous left ventricular assist devices. Catheter Cardiovasc Interv. 2011;78:304 13. 572. Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54:2430 4. 573. Perera D, Stables R, Clayton T, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a random- ized, controlled trial of elective balloon counterpulsation during high- risk percutaneous coronary intervention. Circulation. 2013;127:207 12. 574. Goldberg RJ, Yarzebski J, Spencer FA, et al. Thirty-year trends (1975- 2005) in the magnitude, patient characteristics, and hospital outcomes of patients with acute myocardial infarction complicated by ventricular fibrillation. Am J Cardiol. 2008;102:1595 601. 575. Gupta S, Pressman GS, Figueredo VM. Incidence of, predictors for, and mortality associated with malignant ventricular arrhythmias in non-ST elevation myocardial infarction patients. Coron Artery Dis. 2010;21:460 5. 576. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol. 1997;80: 35J 9J. 577. Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycar- dia. J Am Coll Cardiol. 2012;60:1993 2004. 578. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994;127:1139 44. 579. Connolly SJ, Hallstrom AP, Cappato R, et al.


1994;127:1139 44. 579. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. CardiacArrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071 8. 580. A comparison of antiarrhythmic-drug therapy with implantable defibril- lators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576 83. 581. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibril- lator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. 582. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormali- ties: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. [published correction appears in Circulation. 2009;120:e34-35]. Circulation. 2008;117:e350 408. 583. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide- lines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Circulation. 2006;114:1088 132. 584. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and out- comes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009;30:2019 28. 585. Lean & MasterACLS.Available at: http://acls-algorithms.com/vfpulseless-vt. Accessed July 30, 2014. 586.


Lean & MasterACLS.Available at: http://acls-algorithms.com/vfpulseless-vt. Accessed July 30, 2014. 586. Hreybe H, Saba S. Location of acute myocardial infarction and associ- ated arrhythmias and outcome. Clin Cardiol. 2009;32:274 7. 587. Newby KH, Pisano E, Krucoff MW, et al. Incidence and clinical rel- evance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy. Circulation. 1996;94:2424 8. 588. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511 5. 589. Jeger RV, Urban P, Harkness SM, et al. Early revascularization is benefi- cial across all ages and a wide spectrum of cardiogenic shock severity: a pooled analysis of trials. Acute Card Care. 2011;13:14 20. 590. Lim HS, Farouque O,Andrianopoulos N, et al. Survival of elderly patients undergoing percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock. JACC Cardiovasc Interv. 2009;2:146 52. 591. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448 54. 592. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine ace- tate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297:1657 66. 593. Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med. 2004;164:1457 63. 594. Awad HH, Anderson FA Jr., Gore JM, et al. Cardiogenic shock compli- cating acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. Am Heart J. 2012;163:963 71. 595. Jacobs AK, French JK, Col J, et al. Cardiogenic shock with non-ST- segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK?


Cardiogenic shock with non-ST- segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK? J Am Coll Cardiol. 2000;36:1091 6. 596. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779 89. 597. Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardio- genic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30:2102 8. 598. Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra- aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003; 108:951 7. 599. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clini- cal study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.Am Heart J. 2006;152. 469 8. 600. Seyfarth M, Sibbing D, Bauer I, et al.A randomized clinical trial to evalu- ate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584 8. 601. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consider- ation of the extent of coronary artery disease and benefits of revascular- ization. J Am Coll Cardiol. 2004;43:585 91. 602. Silva JA, Escobar A, Collins TJ, et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation. 1995;92:1731 6. 603. Elbarouni B, Ismaeil N, Yan RT, et al.


1995;92:1731 6. 603. Elbarouni B, Ismaeil N, Yan RT, et al. Temporal changes in the manage- ment and outcome of Canadian diabetic patients hospitalized for non-ST- elevation acute coronary syndromes. Am Heart J. 2011;162:347 55. 604. Kristensen TS, Kofoed KF, Kuhl JT, et al. Prognostic implications of nonobstructive coronary plaques in patients with non-ST-segment eleva- tion myocardial infarction: a multidetector computed tomography study. J Am Coll Cardiol. 2011;58:502 9. 605. Sanchez PL, Morinigo JL, Pabon P, et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart. 2004;90:264 9. 606. Ting HH, Chen AY, Roe MT, et al. Delay from symptom onset to hospi- tal presentation for patients with non-ST-segment elevation myocardial infarction. Arch Intern Med. 2010;170:1834 41. 607. Hasin T, Hochadel M, Gitt AK, et al. Comparison of treatment and out- come of acute coronary syndrome in patients with versus patients with- out diabetes mellitus. Am J Cardiol. 2009;103:772 8. 608. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glu- cose control in critically ill patients. N Engl J Med. 2009;360:1283 97. 609. Rao SV, Ou FS, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008;1:379 86. 610. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interven- tional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349 56. 611. ChaseAJ, Fretz EB,WarburtonWP, et al.Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94:1019 25. 612.


ChaseAJ, Fretz EB,WarburtonWP, et al.Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94:1019 25. 612. Bakhai A, Collinson J, Flather MD, et al. Diabetic patients with acute coronary syndromes in the UK: high risk and under treated. Results from the prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK). Int J Cardiol. 2005;100:79 84. 613. Groot MW, Head SJ, Bogers AJ, et al. Coronary revascularization in diabetic patients. A focus on the 3-year SYNTAX trial outcomes. Herz. 2012;37:281 6. 614. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percu- taneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55:432 40. 615. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multives- sel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575 81. 616. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for mul- tivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375 84. 617. Feit F, Manoukian SV, Ebrahimi R, et al. Safety and efficacy of bivali- rudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from theACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2008;51:1645 52. 618. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic out- comes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation.